Clinical Trial Update: A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin [Phase 1]

View source ↗

Summary

Pfizer conducted a Phase 1 trial in healthy subjects to evaluate single-dose subcutaneous administration of PF-05230901; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cachexia

Drugs mentioned

• PF-05230901 (PF-05230901)

Snippet

Sponsor: Pfizer | Conditions: Cachexia | Phase 1 | Status: TERMINATED